Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Long-Term Debt Repayments (2018 - 2025)

Nutex Health's Long-Term Debt Repayments history spans 8 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 87.11% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $11.4 million, up 14.17%, while the annual FY2025 figure was $11.4 million, 14.17% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $3.1 million at Nutex Health, up from $2.6 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $13.7 million in Q2 2021 and bottomed at -$16.2 million in Q4 2021.
  • The 5-year median for Long-Term Debt Repayments is $2.6 million (2022), against an average of $2.3 million.
  • The largest YoY upside for Long-Term Debt Repayments was 23052.48% in 2021 against a maximum downside of 1223.68% in 2021.
  • A 5-year view of Long-Term Debt Repayments shows it stood at -$16.2 million in 2021, then skyrocketed by 115.5% to $2.5 million in 2022, then skyrocketed by 135.31% to $5.9 million in 2023, then tumbled by 72.35% to $1.6 million in 2024, then soared by 87.11% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Long-Term Debt Repayments are $3.1 million (Q4 2025), $2.6 million (Q3 2025), and $3.9 million (Q2 2025).